Use of orlistat in obese, dyslipidemic patients

By H Nelson Robert   M Miles John  

Future Lipidology, Vol. 1, Iss. 3, 2006-06 ,pp. : 267-273

Future Medicine

Access to resources Recommend Favorite

Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study

By Filippatos T. D.   Kiortsis D. N.   Liberopoulos E. N.   Georgoula M.   Mikhailidis D. P.   Elisaf M. S.  

Current Medical Research and Opinion, Vol. 21, Iss. 12, 2005-12 ,pp. : 1997-2006

Informa Healthcare

Access to resources Recommend Favorite

The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia

By Nakou E. S.   Filippatos T. D.   Georgoula M.   Kiortsis D. N.   Tselepis A. D.   Mikhailidis D. P.   Elisaf M. S.  

Current Medical Research and Opinion, Vol. 24, Iss. 7, 2008-07 ,pp. : 1919-1929

Informa Healthcare

Access to resources Recommend Favorite

Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: a systematic review and meta‐analysis of randomized controlled trials

By  

OBESITY REVIEWS, Vol. 16, Iss. 12, 2015-12 ,pp. : 1071-1080

John Wiley & Sons Inc

Access to resources Recommend Favorite

Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom

By Thompson Melissa  

Journal of Medical Economics, Vol. 16, Iss. 6, 2013-06 ,pp. : 744-755

Informa Healthcare

Access to resources Recommend Favorite